Company profile
Allogene Therapeutics, Inc.
NASDAQ: ALLO · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
39DFH 42DQ 40GM 15SS 62
v0.1 · 65/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$190.9M
Employees
151
as of 2026-08-11
Market cap
$724.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$190.9M-$190.9M2025
Operating income-$209.3M-$209.3M2025
Total assets$415.9M$415.9M2025
Liabilities$123.4M$123.4M2025
Equity$292.5M$292.5M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Allogene Therapeutics, Inc.’s revenue?
Allogene Therapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Cullinan Therapeutics, Inc.50DDesign Therapeutics, Inc.55CMonopar Therapeutics Inc.59CAchieve Life Sciences, Inc.37DNeurogene Inc.43DArtiva Biotherapeutics, Inc.41DNeighbors
San Mateo →Key facts
CEOZachary Roberts
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ALLO
Employees151
IPO date2018-10-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.